Effects of drug resistance in the tumour-immune system with chemotherapy treatment
José Trobia, Enrique C Gabrick, Evandro G Seifert, Fernando S Borges, Paulo R Protachevicz, José D Szezech, Kelly C Iarosz, Moises S Santos, Iberê L Caldas, Kun… 展开作者
José Trobia, Enrique C Gabrick, Evandro G Seifert, Fernando S Borges, Paulo R Protachevicz, José D Szezech, Kelly C Iarosz, Moises S Santos, Iberê L Caldas, Kun Tian, Hai-Peng Ren, Celso Grebogi, Antonio M Batista
Cancer is a term used to refer to a large set of diseases. The cancerous cells grow and divide and, as a result, they form tumours that grow in size. The immune system recognise the cancerous cells and attack them, though, it can be weakened by the cancer. One type of cancer treatment is chemotherapy, which uses drugs to kill cancer cells. Clinical, experimental, and theoretical research has been developed to understand the dynamics of cancerous cells with chemotherapy treatment, as well as the interaction between tumour growth and immune system. We study a mathematical model that describes the cancer growth, immune system response, and chemotherapeutic agents. The immune system is composed of resting cells that are converted to hunting cells to combat the cancer. In this work, we consider drug sensitive and resistant cancer cells. We show that the tumour growth can be controlled not only by means of different chemotherapy protocols, but also by the immune system that attacks both sensitive and resistant cancer cells. Furthermore, for all considered protocols, we demonstrate that the time delay from resting to hunting cells plays a crucial role in the combat against cancer cells.
Immunometabolic Gatekeeping: Reconciling Peto's & the T-cell Infiltration Prognostic Paradox
The Francis Crick Institute（弗朗西斯·克里克研究所）；Cancer Research UK Manchester Institute, The University of Manchester（曼彻斯特大学癌症研究英国曼彻斯特研究所）；Cancer Research UK Scotland Institute, University of Glasgow（格拉斯哥大学癌症研究英国苏格兰研究所）；School of Cancer Sciences, University of Glasgow（格拉斯哥大学癌症科学学院）；Department of Bioengineering, Imperial College London（帝国理工学院生物工程系）；The Institute of Cancer Research（癌症研究所）；Centre for Genetics and Genomics, UCL Department of Renal Medicine, UCL Medical School（伦敦大学学院医学院肾脏医学系基因与基因组中心）；The Christie NHS Foundation Trust（克里斯蒂NHS基金会信托）
Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations
School of Mathematics and Statistics, University of Sydney（悉尼大学数学与统计学院）；Department of Immuno-Oncology, Beckman Research Institute, City of Hope（希科医院贝克曼研究所免疫肿瘤学系）
